72.19.Z - Other research and experimental development on natural sciences and engineering
71.11.Z - Architectural activities
71.12.Z - Engineering activities and related technical consultancy
71.20.B - Other technical testing and analysis
72.11.Z - Research and experimental development on biotechnology
72.20.Z - Research and experimental development on social sciences and humanities
74.10.Z - Specialised design activities
74.90.Z - Other professional, scientific and technical activities not elsewhere classified
86.90.A - Physiotherapeutical activities
86.90.D - Paramedical activities
2021 | 2022 | 2023 | ||
---|---|---|---|---|
K PLN | K PLN | K PLN | % | |
Profit (loss) on sale | 40 | 29,6 | 409,1 | 1282,5 |
Gross profit (loss) | 40,2 | 8,9 | 409,1 | 4521,9 |
EBITDA | 16,8 | 409,1 | 2332,1 | |
Short time liabilities | 0 | 36,6 | 51,3 | 40 |
Other operating costs | 0 | 13,1 | 0 | -100 |
Equity capital | 128,9 | 137,7 | 520,9 | 278,2 |
Operating profit (EBIT) | 16,5 | 409,1 | 2386,3 | |
Assets | 164,1 | 174,4 | 572,1 | 228,2 |
Net profit (loss) | 36,3 | 5,3 | 383,1 | 7069,3 |
Cash | 0 | 143,8 | 437,1 | 204 |
Net income from sale | 124,7 | 215,5 | 662,6 | 207,4 |
Liabilities and provisions for liabilities | 0 | 36,6 | 51,3 | 40 |
Working assets | 163,7 | 174,4 | 572,1 | 228,2 |
Other income costs | 0 | 0 | -∞ | |
Depreciation | 0,9 | 0,4 | 0 | -100 |
% | % | % | p.p. | |
Profitability of capital | 28,2 | 3,9 | 73,6 | 69,7 |
Equity capital to total assets | 78,6 | 79 | 91 | 12 |
Gross profit margin | 32,2 | 4,1 | 61,7 | 57,6 |
EBITDA Margin | 7,8 | 61,7 | 53,9 | |
Days | Days | Days | Days | |
Short term commitment turnover cycle | 0 | 62 | 28 | -34 |
Current financial liquidity indicator | 4.761292934417725 | 11.160785675048828 | 6,4 |
Opinie dotyczące usług, produktów oraz działalności firmy nie są weryfikowane